FAAH inhibitors in the limelight, but regrettably
- PMID: 27191771
- PMCID: PMC4941643
- DOI: 10.5414/CP202687
FAAH inhibitors in the limelight, but regrettably
Abstract
This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events.
References
-
- Pertwee RG Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc Nutr Soc. 2014; 73: 96–105. - PubMed
-
- Fowler CJ The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs – A practical view. Eur Neuropsychopharmacol. 2015; 25: 749–762. - PubMed
-
- Mazier W Saucisse N Gatta-Cherifi B Cota D The endocannabinoid system: pivotal orchestrator of obesity and metabolic disease. Trends Endocrinol Metab. 2015; 26: 524–537. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical